RxDoctor Payments Data

Michael Peck, DO

Family Medicine · Plymouth Meeting, PANPI 1265427306

Payments from drug & device makers

$1,833in general payments, 2019–2025

Across 71 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$593
  • Amgen$59
  • E.r. Squibb & Sons, L.L.C.$47
  • Acadia Pharmaceuticals Inc$32
  • Tactile Systems Technology Inc$23
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$1,69392%
  • Education$1398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,833 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$174,378
Medicare patients
813
Services billed
1,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban676$191,389
TrulicityDulaglutide54$52,751
XareltoRivaroxaban144$41,878
AbrysvoRsv Vacc, Pref A And Pref B/Pf107$33,806
JardianceEmpagliflozin143$30,071
NuplazidPimavanserin Tartrate11$28,268
MyrbetriqMirabegron104$27,946
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,573
JanuviaSitagliptin Phosphate116$20,548
RexultiBrexpiprazole27$20,374
EntrestoSacubitril/Valsartan57$15,560
Atorvastatin Calcium1,491$15,303
NuedextaDextromethorphan Hbr/Quinidine17$12,872
Memantine Hcl450$10,608
Gabapentin766$9,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$15$225,195783 claims
Acadia Pharmaceuticals IncNuplazid$32$28,26811 claims
Otsuka America Pharmaceutical, Inc.Rexulti$593$20,37427 claims
Sunovion Pharmaceuticals Inc.Latuda$1,012$9,43117 claims
Sumitomo Pharma America, Inc.Gemtesa$23$7,97633 claims
AstraZenecaBrilinta$12$6,20019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →